Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

Bioadaptives (BDPT) Revenue (2019 - 2025)

Historic Revenue for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to $4632.0.

  • Bioadaptives' Revenue changed N/A to $4632.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $7851.0, marking a year-over-year decrease of 6048.82%. This contributed to the annual value of $12669.0 for FY2024, which is 5564.85% down from last year.
  • Per Bioadaptives' latest filing, its Revenue stood at $4632.0 for Q3 2025.
  • Over the past 5 years, Bioadaptives' Revenue peaked at $15649.0 during Q3 2023, and registered a low of $675.0 during Q2 2024.
  • For the 5-year period, Bioadaptives' Revenue averaged around $5377.3, with its median value being $4420.0 (2021).
  • In the last 5 years, Bioadaptives' Revenue plummeted by 7114.15% in 2024 and then soared by 37688.89% in 2025.
  • Over the past 5 years, Bioadaptives' Revenue (Quarter) stood at $3851.0 in 2021, then rose by 3.45% to $3984.0 in 2022, then soared by 80.75% to $7201.0 in 2023, then tumbled by 90.63% to $675.0 in 2024, then skyrocketed by 586.22% to $4632.0 in 2025.
  • Its Revenue stands at $4632.0 for Q3 2025, versus $3219.0 for Q2 2025 and $675.0 for Q2 2024.